Upstream cell culture process characterization and in-process control strategy development at pandemic speed

As of early 2022, the coronavirus disease 2019 (COVID-19) pandemic remains a substantial global health concern. Different treatments for COVID-19, such as anti-COVID-19 neutralizing monoclonal antibodies (mAbs), have been developed under tight timelines. Not only mAb product and clinical development...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jianlin, Ou, Jianfa, McHugh, Kyle P., Borys, Michael C., Khetan, Anurag
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986202/
https://www.ncbi.nlm.nih.gov/pubmed/35380922
http://dx.doi.org/10.1080/19420862.2022.2060724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986202/
https://www.ncbi.nlm.nih.gov/pubmed/35380922
http://dx.doi.org/10.1080/19420862.2022.2060724

Ejemplares similares